Serological Pipettes Market Analysis & Forecast: 2026-2033
The Serological Pipettes Market size is anticipated to grow at a CAGR of 5.1% with USD 270 Mn in 2026 and is expected to reach USD 380 Mn in 2033. The primary drivers are defined by rising life science research activity, increasing adoption of cell culture, microbiology, diagnostics, and biopharmaceutical manufacturing, and growing demand for accurate, sterile, and contamination-free liquid handling. Some of the other factors include expansion of academic research laboratories, higher vaccine and biologics production, growing pharmaceutical R&D outsourcing, increasing use of disposable plastic labware, automation-compatible workflows, and stricter laboratory quality standards. According to ClinicalTrials.gov, over 584,000 studies are listed globally, reinforcing demand for serological pipettes across research laboratories.
On the basis of product, the 5 ml segment is projected to account for the largest Serological Pipettes Market share of 28.5% in 2026. The segment’s growth is owing to its suitability for routine liquid handling, small-batch media transfer, reagent preparation, bacterial culture inoculation, and cell culture workflows. The 5 ml size offers a practical balance between precision and usable volume, thereby making it useful in research labs, academic institutions, hospital laboratories, and pharmaceutical quality control facilities. The firm, Corning, states that serological pipets are available in multiple sizes from 1 ml to 100 ml, thus indicating broad volume-based adoption in bacteriological research applications.
The segment also benefits from the rise of clinical and translational research. ClinicalTrials.gov reported more than 530,000 total studies in 2025, thereby reflecting large-scale research activity that requires routine lab consumables like pipettes, pipette controllers, tubes, plates, and sterile media handling products.
To learn more about this report, Request Free Sample
On the basis of material, the plastic pipettes segment lead with a major 40.5% share in 2026. The growth is owing to the sterility, disposability, convenience, reduced cross-contamination risk, and compatibility with aseptic workflows. Plastic serological pipettes are extensively preferred in clinical research, microbiology, cell culture, pharmaceutical QC, and biotechnology laboratories because they eliminate washing and sterilization steps associated with reusable glass pipettes. VWR states that disposable polystyrene serological pipettes are used for sterile serological and tissue culture applications and include features like negative graduations, color coding, and ±2% accuracy at full volume.
Plastic pipettes also support both biosafety as well as infection control requirements. The CDC guidance for clinical specimen handling emphasizes standard precautions because clinical specimens may contain infectious materials. This strengthens the value of sterile, single-use consumables in laboratories handling patient samples, microbial cultures, or potentially infectious materials.
Europe is witnessing rising innovation in sustainable sterile labware supported by the growing institutional focus on reducing laboratory plastic waste, improving procurement transparency, and adopting third-party verified environmental labels. Serological pipettes are essential for sterile liquid transfer, but their disposable plastic nature creates sustainability pressure for laboratories and manufacturers. As a result, the suppliers are focusing on packaging optimization, recyclable materials, environmental labeling, as well as manufacturing transparency. The EU Packaging and Packaging Waste Regulation entered into force on February 11, 2025, and will generally apply from August 12, 2026, thereby pushing suppliers to rethink packaging formats and recyclability.
In September 2024, Greiner Bio-One announced that its serological pipettes received the ACT ecolabel from My Green Lab, thus making sustainability performance more transparent for the laboratory buyers. The development supports procurement decisions by giving laboratories third-party verified environmental information for life science products. This is expected to strengthen adoption of sustainable liquid handling consumables and encourage competing suppliers to invest in lower-impact packaging and product design for serological pipettes.
Smart pipette controllers are becoming an important breakthrough in the serological pipettes market because they improve comfort, accuracy, repeat dispensing, and workflow efficiency during manual liquid transfer. Traditional serological pipetting depends on operator control, which can create variability during repeated aliquoting, media changes, cell culture feeding, or reagent dispensing. The advanced controllers help reduce repetitive hand strain and support more consistent flow control, especially when handling sensitive cell monolayers, bacterial cell cultures, or multi-well plate workflows.
In September 2024, INTEGRA Biosciences launched the PIPETBOY GENIUS serological pipet controller. It featured repeat dispense capability for aliquots from 0.1 ml to 50 ml, along with overfill protection. The firm stated that the product allows the users to aspirate the required volume and perform consistent repeat dispensing by pressing a button. This is important for cell culture laboratories, microbiology labs, and biopharma R&D facilities where repeatable sterile dispensing is required.
|
Current Event |
Description and its Impact |
|
2026 Regulatory Tightening on Laboratory Plastic Consumables in the U.S. and EU |
|
|
Global Shift Toward Certified Medical Device Manufacturing Standards (ISO 13485 & GMP Alignment) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 35.4% of the market share in 2026. The region’s growth is owing to advanced biomedical research infrastructure, high clinical trial activity, strong pharmaceutical R&D spending, and established procurement networks for laboratory consumables. The U.S. remains the largest demand contributor due to its concentration of pharmaceutical companies, biotechnology firms, academic medical centers, diagnostic laboratories, and contract research organizations.
The NSF reported that the U.S. recorded USD 923.2 billion in gross domestic R&D expenditure. Also, the NIH awarded USD 35.3 billion in biomedical research grants in FY 2025. These funding levels promote the continuous laboratory activity and recurring purchases of sterile liquid handling consumables.
In August 2025, Thermo Fisher Scientific opened a manufacturing center of excellence in Mebane, North Carolina, to strengthen the U.S. production of laboratory liquid handling consumables. The 375,000-square-foot site is capable of producing at least 40 million pipette tips per week, thereby supporting the broader demand for sterile plastic labware used in research, diagnostics, and biopharmaceutical workflows.
Asia Pacificis expected to witness strong growth in Serological Pipettes Market over the forecast period. The region’s growth is owing to the rising biotechnology investment, expanding pharmaceutical manufacturing, increasing diagnostic laboratory capacity, and government-backed biomanufacturing initiatives across India, China, Japan, South Korea, Singapore, and ASEAN countries.
According to Eurostat, China’s R&D intensity reached 2.58% of GDP in 2023, while South Korea recorded 4.96%, indicating strong research intensity in Asia’s major innovation economies. Singapore is important due to its biomedical manufacturing base. Singapore EDB states that eight of the world’s top 10 biopharmaceutical companies conduct manufacturing or R&D activities in the country. This supports demand for sterile liquid handling products used in R&D, process development, and quality control.
The United States Serological Pipettes Market is driven by strong biomedical R&D expenditure, expanding biopharmaceutical manufacturing, and high clinical trial density across academic and commercial laboratories. According to the National Science Foundation (NSF), the U.S. R&D expenditure reached USD 886 billion in 2022, thereby strengthening the continual demand for laboratory consumables used in research workflows. In addition, the FDA approved 46 novel drugs in 2025, thereby highlighting the sustained drug development activity that increases reliance on sterile liquid handling tools in preclinical and clinical laboratories.
In July 2025, Thermo Fisher Scientific announced the expansion of its sterile manufacturing capabilities in the United States through acquisition and upgrading of a fill-finish facility in New Jersey. The expansion is aimed at increasing the production of sterile pharmaceutical materials and promoting the advanced biologics manufacturing. This development strengthens the domestic supply chain for laboratory consumables and also aligns with the growing demand from biotech and pharmaceutical companies.
India is expected to show strong growth in the Serological Pipettes Market due to expansion of biotechnology, vaccine manufacturing, pharmaceutical R&D, diagnostics, and academic research infrastructure. Serological pipettes are widely used in Indian laboratories for microbiology, cell culture, bacterial culture, media transfer, reagent preparation, and QC testing.
According to PIB, India’s bioeconomy reached USD 195.3 billion in 2025, reflecting 18% annual growth. PIB also reported that India’s biotech startup ecosystem reached 13,000 startups in 2025, supported by BIRAC programs and increased investment. These developments are expected to increase demand for sterile plastic lab consumables, including serological pipettes.
Some of the major key players in Serological Pipettes Market are Thermo Fisher Scientific, Corning, VWR, Sarstedt AG & Co., KG, Merck, Eppendorf, Argos Technologies, Camlab, HiMedia Laboratories, Greiner Bio-One, Biofil, Vitrolife, Kimble Chase, CITOTEST, Sorfa, and Daigger.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 270 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.1% | 2033 Value Projection: | USD 380 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Corning, VWR, Sarstedt AG & Co., KG, Merck, Eppendorf, Argos Technologies, Camlab, HiMedia Laboratories, Greiner Bio-One, Biofil, Vitrolife, Kimble Chase, CITOTEST, Sorfa, and Daigger. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
